about us | newsletter | contact | archive | members area
Nicolae Ghibu, Certsign
Regulations will come gradually and will cover all areas»
  Features:      COUNTRY FOCUS   |   SECTOR ANALYSIS   |

Prescription for growth: Dan Zamonea, Roche Romania

Sudden market leader in pharma sales for 2008, Roche Romania’s Dan Zamonea talks to Michael Bird

March 2009 - From the Print Edition

It was not our objective to become number one,” says Dan Zamonea, general manager of Roche Romania, on the news that the affiliate he oversees has overtaken GlaxoSmithKline to become market leader in pharma sales in Romania.
The local branch of the Swiss group posted a market share of 7.3 per cent and sales of 521 million RON (around 140 million Euro) for 2008, according to local pharma association Cegedim.
Zamonea says Roche is not aiming for size, but to lead in therapies where it specialises, such as oncology, anaemia, virology and transplants. “Our main goal in every market and Romania is to try to strive to bring these drugs to as many patients as possible,” he says.
Globally, many pharma firms are in acquisition frenzy with giant over-the-counter medicine firms taking over generic companies. Asked whether Roche is interested in any potential buy-outs in Romania, Zamonea says that from the few pharma companies in the country, most work only in the generic sector. “Acquisition of a generic company is out of our scope,” he adds. Roche only imports pharma for the prescription sector.
Starting production in Romania is also unlikely to happen for Roche. “It wouldn’t make a big difference to the economy because [a factory] mostly involves investment in technology and is not labour intensive,” he adds.
Instead where the company hopes to invest in the long-term in Romania is in research and development. “This could employ more people from the white collar sector which could benefit the local community from a prestigious and financial point of view,” he adds.
The structure could be a partnership with an institution, hospital or university. “If there is a worthwhile idea, we will support, invest and grow together with a respected company, university or team,” he says.
Roche has been approached by hospitals and groups interested in research and the company is trying to identify groups it can support.
In general, Roche supports advanced research in genetics. With the mapping of the human genome now complete, scientific communities around the world are analysing this data to see how it can reveal the cause and effect of different diseases, with a move to finding cures or preventions.
However the problems in Romania for research include a few Government grants, a lack of research infrastructure and few qualified people.

Low spending

Romania has one of the lowest Government spending on healthcare in the EU as a percentage of GDP and among the lowest drug consumption per capita in the region. With the financial crisis seeing Romania’s growth decelerate, this also puts the health industry under pressure. The percentage of Government expenditure on drugs may be similar this year to the last, but there will be some cost savings, says Zamonea. In 2009 and 2008 some important drugs moved from patent to generic – which means their prices drop. “The Government can then expand access of patients to drugs,” he adds.
This trend will continue in 2010 and 2011 as more patented drugs become generic. “This includes some blockbusters – worth billions of dollars on a global scale – and their value will cut by almost half,” he adds. “A lot of funds are released from that.”
The Government sets the exchange rates for which drugs are purchased from abroad between the local currency, the RON, and the Euro. This figure is always controversial because if the local currency drops in value, drug companies end up losing money.
Historically, the state has fixed this for three month periods and, if the span of variation was higher than five per cent, the prices would be updated. But Zamonea says this ‘update’ was theoretical and did not always happen in practice. Between June 2007 and October 2008, the exchange rate remained unchanged at 3.3 RON to the Euro, even though the devaluation of the RON was quite significant. Roche operates in Swiss Francs, where the difference has been even higher. “If the exchange rate went up, we were absorbing the losses,” says Zamonea.
A new law will now fix the exchange rate for one year using the rate on which the national budget is drafted – four RON to the Euro. Zamonea says the new rules at least bring predictability into the sector.
The main diseases ailing Romanians are cardio-vascular and cancer. The country also has high incidences of tuberculosis and Hepatitis B and C compared to west Europe. Roche’s bestselling products in Romania include treatments for anaemia and for Hepatitis B and C.
Roche also supplies the Tamiflu anti-flu vaccine, which can combat the emergence of the bird flu virus in people, should there be an epidemic. Tamiflu blocks the replication of the virus, but only if a doctor administers this within 48 hours of the onset of the disease. The Romanian Government has a small reserve of this vaccine in place. “The batch is minimal,” says Zamonea. “I don’t know if they intend to buy another one. Most other countries in Europe have reserves on stand-by.”
France has reserves covering about 50 per cent of the population and the UK intends to cover around one quarter of its people with Tamiflu and GSK’s Relenza. Romania’s reserves cover 0.1 per cent of the population.
One area of expertise for Roche is in transplant medication. Zamonea says Romania has a good transplant school in Bucharest and several centres developing around the country. The infrastructure is in place and there is activity - around five heart transplants took place in Romania in 2008. “But what is lacking is a culture of donation,” he says.
There are around 2,000 Romanians on a waiting list for transplants, the greatest number for new kidneys. Fresh laws are under debate. At present someone can only grant the use of their organs when brain-dead if they have drawn up a written confirmation, or with consultation with the family. One new law proposes that doctors can harvest organs from a clinically dead patient, unless that person has previously vetoed such a move. However, if the individual has refused to allow their organs to be used for harvesting, that person will not be eligible, if they should be in a critical condition, to receive donated organs. “This can be a motivator [for people to agree to donation],” says Zamonea.
Such a structure has worked in Spain, where the number of transplants subsequently increased.

Taking dose of Roche in Romania

■ Dan Zamonea says Roche only launches drugs on the market if the pharma company can bring a new class of therapeutic drugs or if they are the best in class. “We are not developing and producing me-too drugs,” he adds. “We are not interested in bringing in a molecule and trying to get a 30 per cent market share. We want to be the first or to be the best. If you don’t bring something innovative, new, better and more effective, then you are out of the game. Some big companies lived for a couple of blockbuster drugs and focused on just growing market share. Some are in trouble. Probably some companies will disappear.”
■ In Romania, the pharma company employs over 160 people. The majority are involved in marketing, where these medical representatives cooperate with doctors, identify the best drugs for patients or work in analysis, testing, certifying and keeping updated on new clinical data. The Romanian affiliate is part of the Swiss Roche group, which is still majority owned by the Swiss Roche family.

Who is Dan Zamonea?
■ After studying optical and medical equipment engineering at Bucharest’s Politehnica University, Dan Zamonea worked as an engineer selling technical services to other industrial companies for electrical equipment installers Imsat. This was a state-owned company which, in the 1980s, had to compete for funds from other state companies. It had a profit centre and staff were paid on the new business they brought in. “We had to be entrepreneurial from that moment,” Zamonea says. In 1992, he moved to Colgate Palmolive as a sales manager, while completing his MBA.
■ He then worked for US pharma group Warner Lambert, where he became regional manager responsible for the Balkans, which extended to Malta, Gibraltar, Iceland and the Baltic states. In 2001 moved to Roche, which then had a representative office open, before it became a local affiliate in 2005 and Zamonea became general manager.



COMMENTS
There are 0 comments:

 
ADD A COMMENT
 
Name
Email
Comment
Validation Code
   
 
 

0 Comments  |  6985 Views
Daily Info
OTP Bank Romania to double its IT team to support its digital development plans

OTP Bank Romania will double its IT team in order to support its digital development plans for next year.

Black Sea Oil & Gas signs the gas sales agreement with Engie for natural gas supply from the MGD project

Black Sea Oil & Gas together with its co-venture partners, Petro Ventures Resources and Gas Plus International, announced the signing of the gas sales agreement with Engie thr...

Bucharest Stock Exchange and other capital market representatives establish the Romanian Investor Relations Association

Companies listed on the Bucharest Stock Exchange (BVB), those with potential to become listed companies jointly with funds managers and Investor Relations (IR) professionals f...

GapMinder fund invests in FintechOS, a start-up that develops AI solutions for the financial services industry

FintechOS, a company specializing in accelerating the digital transformation of financial institutions, has attracted 600,000 Euro of funding from the GapMinder investment fun...

The Romanian labour market needs a well-thought approach, says FIC

The Foreign Investors Council (FIC) has signaled in the past 2-3 years that its members are anticipating increasing strains on the Romanian labour market because starting with...

 
 
   
advertising

advertising

advertising

More on Features
Cryptocurrency exchanges. The new outsourcing El Dorado?

Customer experience has become the new competitive battleground for crypto exchanges. Cryptocurrency exchanges seeking to maintain or gain an advantage in this highly comp...

Blockchain how it's made and what can we do with it

In the context of the "fourth industrial revolution" that everyone is talking about these days, The Diplomat - Bucharest analyses how an emerging technology like blockchain...

French investments at a glance: Interest still high

France, Romania's fourth largest foreign direct investor, has been around since the early 1990s, with flagship names the likes of Societe Generale or Groupe Renault taking ...

US calls for coherent, long-term strategy

As USA celebrates 4th of July, its eyes are wide open on the latest developments in Romania's ongoing struggle for the rule of law. Still, the country is one of the fastest...

Romanian energy industry: Challenges to Overcome

With a national strategy draft still to be approved, Romania faces many challenges, as the energy market is striving to find a way to attract major investments that are cri...

Romanian office market ripening, in both leasing and acquisition

From the investment standpoint, lower rates of return and increased liquidity lure the investors, Andreea Paun, Managing Partner, Griffes said in an interview for The Diplo...

ISS: External FM market volume will grow as more Western European FM companies open subsidiaries in Romania

In the last few years as well as in 2017, the Romanian FM market has been in the process of maturing, focusing more and more on quality, efficiency and added value, demandi...